Frost & Sullivan: Female Cancer Patients More Willing To Use Implantable Infusion Pumps Than Males

Main Category: Cancer / Oncology
Also Included In: Medical Devices / Diagnostics
Article Date: 23 Apr 2009 - 4:00 PDT

email to a friend   printer friendly   opinions  

The latest end-user study from Frost & Sullivan's Pharmaceuticals & Biotechnology group assesses a variety of critical dynamics of drug delivery approaches and technologies in cancer treatment. Physicians, nurses and patients provided insight on factors such as perception, usage, reconstitution, home vs. office administration parameters, and barriers of leading drug delivery types, providing insight and feedback to cancer treatment developers.

Selected findings from the survey include the following:

-- Nearly half of cancer patients surveyed wanted home infusion to last less than 1 hour.

-- Infusion nurses expected greater change in prescribing trends for cancer drug treatment over the next 12-24 months than oncologists.

-- Cancer patients were highly satisfied with implantable fusion pumps and oral delivery. While 75 percent of patients conduct drug delivery by themselves or a family member, oncologists and infusion nurses prefer this process be conducted by a trained healthcare worker or caregiver.

-- Oncologists and infusion nurses prefer oral as the leading type for new drug development, although other types were highly valued such as implants, transdermal patches, and implantable infusion pumps

Through more than 240 detailed interviews with medical oncologists, infusion nurses and cancer patients (breast, colorectal, lung, prostate) in the U.S., research analysts identified key insights into drug treatment, utilization, and potential future approaches to drug delivery in oncology.

From the Analyst

"Understanding the views and desires of end users regarding cancer drug delivery is an important asset to pharmaceutical and biotechnology companies," notes Frost & Sullivan Pharmaceuticals & Biotechnology Industry Manager Daniel Ruppar.

"As companies seek new opportunities in cancer treatment, an understanding of users' views of drug delivery factors from several sides could influence and generate innovative portfolio and development decisions," explains Ruppar. "By understanding the needs, preferences, and other points of feedback of the delivery of cancer drugs from oncologists, infusion nurses and patients, developers can glean insight from viewpoints across the cancer treatment pathway."

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents.

Source: Frost & Sullivan

• Additional
• References
• Citations